ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,107 | -99.9% | 50,000 | 0.0% | 0.41% | +13.3% |
| Q3 2022 | $5,163,000 | +11.1% | 50,000 | 0.0% | 0.36% | +2.8% |
| Q2 2022 | $4,648,000 | -20.8% | 50,000 | 0.0% | 0.35% | -22.2% |
| Q1 2022 | $5,868,000 | -12.8% | 50,000 | 0.0% | 0.45% | +12.8% |
| Q4 2021 | $6,726,000 | -75.2% | 50,000 | -70.6% | 0.40% | -63.7% |
| Q3 2021 | $27,096,000 | +174.6% | 170,000 | +126.7% | 1.10% | +228.7% |
| Q2 2021 | $9,866,000 | -23.4% | 75,000 | -25.0% | 0.34% | +16.7% |
| Q1 2021 | $12,888,000 | -22.7% | 100,000 | 0.0% | 0.29% | -27.7% |
| Q4 2020 | $16,678,000 | -13.5% | 100,000 | -20.0% | 0.40% | -46.5% |
| Q3 2020 | $19,290,000 | -25.5% | 125,000 | -28.6% | 0.74% | -24.9% |
| Q2 2020 | $25,883,000 | -61.7% | 175,000 | -70.8% | 0.99% | -68.5% |
| Q1 2020 | $67,567,000 | -25.3% | 600,000 | -7.7% | 3.14% | -13.0% |
| Q4 2019 | $90,428,000 | +30.7% | 650,000 | -9.5% | 3.61% | -14.3% |
| Q3 2019 | $69,187,000 | -7.6% | 718,300 | +10.5% | 4.21% | -2.0% |
| Q2 2019 | $74,848,000 | +6.0% | 650,000 | +8.3% | 4.30% | -9.9% |
| Q1 2019 | $70,620,000 | +233.1% | 600,000 | +77.3% | 4.77% | +177.2% |
| Q4 2018 | $21,204,000 | -14.5% | 338,456 | -3.3% | 1.72% | +6.8% |
| Q3 2018 | $24,801,000 | +0.3% | 350,000 | -5.8% | 1.61% | -11.9% |
| Q2 2018 | $24,728,000 | +1.7% | 371,739 | 0.0% | 1.83% | +1.0% |
| Q1 2018 | $24,312,000 | +102.3% | 371,739 | +23.9% | 1.81% | +44.0% |
| Q4 2017 | $12,018,000 | +329.2% | 300,000 | +200.0% | 1.26% | +209.1% |
| Q1 2017 | $2,800,000 | -14.7% | 100,000 | -38.4% | 0.41% | -8.1% |
| Q4 2016 | $3,284,000 | +162.5% | 162,254 | +160.6% | 0.44% | +221.0% |
| Q3 2016 | $1,251,000 | +51.5% | 62,254 | 0.0% | 0.14% | +17.9% |
| Q2 2016 | $826,000 | -27.6% | 62,254 | +1.2% | 0.12% | -32.0% |
| Q1 2016 | $1,141,000 | +1.2% | 61,500 | 0.0% | 0.17% | +27.4% |
| Q4 2015 | $1,127,000 | +3.5% | 61,500 | 0.0% | 0.14% | -22.4% |
| Q3 2015 | $1,089,000 | +0.2% | 61,500 | 0.0% | 0.17% | +20.0% |
| Q2 2015 | $1,087,000 | +1.9% | 61,500 | 0.0% | 0.14% | -12.1% |
| Q1 2015 | $1,067,000 | – | 61,500 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |